Clinical Trial

A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of SKB264 in patients with unresectable locally advanced, recurrent, or metastatic HR+/HER2- breast cancer who have previously failed endocrine therapy.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-07-08; most recent amendment 2026-05-05.
Status change: Not Yet Recruiting → Recruiting 2025-08-12
Trial Details
NCT Number NCT07071337
Lead Sponsor Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Conditions Metastatic Breast Cancer
Enrollment 430 participants
Start Date 2025-07-18
Primary Completion 2027-07 (estimated)
Study Completion 2031-02 (estimated)
Updated on ClinicalTrials.gov 2026-05-08